EE200000740A - Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma ägedate seisundite vältimiseksvõi raviks - Google Patents

Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma ägedate seisundite vältimiseksvõi raviks

Info

Publication number
EE200000740A
EE200000740A EEP200000740A EEP200000740A EE200000740A EE 200000740 A EE200000740 A EE 200000740A EE P200000740 A EEP200000740 A EE P200000740A EE P200000740 A EEP200000740 A EE P200000740A EE 200000740 A EE200000740 A EE 200000740A
Authority
EE
Estonia
Prior art keywords
budesonide
prevention
treatment
pharmaceutical composition
composition containing
Prior art date
Application number
EEP200000740A
Other languages
English (en)
Inventor
Ekstr�m Tommy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20411658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200000740(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200000740A publication Critical patent/EE200000740A/et
Publication of EE05661B1 publication Critical patent/EE05661B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EEP200000740A 1998-06-11 1999-06-10 Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma „gedate seisundite v„ltimiseks v?i raviks EE05661B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802073A SE9802073D0 (sv) 1998-06-11 1998-06-11 New use
PCT/SE1999/001031 WO1999064014A1 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma

Publications (2)

Publication Number Publication Date
EE200000740A true EE200000740A (et) 2002-04-15
EE05661B1 EE05661B1 (et) 2013-06-17

Family

ID=20411658

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000740A EE05661B1 (et) 1998-06-11 1999-06-10 Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma „gedate seisundite v„ltimiseks v?i raviks

Country Status (34)

Country Link
US (2) US20010049396A1 (et)
EP (3) EP2266574A1 (et)
JP (1) JP2002517450A (et)
KR (1) KR20010052721A (et)
CN (1) CN100389771C (et)
AR (1) AR018410A1 (et)
AT (1) ATE389409T1 (et)
AU (1) AU771715B2 (et)
BR (1) BR9911073A (et)
CA (1) CA2334411C (et)
CY (1) CY1110376T1 (et)
CZ (1) CZ300874B6 (et)
DE (1) DE69938390T2 (et)
DK (1) DK1085877T3 (et)
EE (1) EE05661B1 (et)
ES (1) ES2302384T3 (et)
HU (1) HUP0103108A3 (et)
ID (1) ID27937A (et)
IL (2) IL139921A0 (et)
IS (1) IS5752A (et)
MY (1) MY129281A (et)
NO (3) NO20006253L (et)
NZ (1) NZ536279A (et)
PL (1) PL344665A1 (et)
PT (1) PT1085877E (et)
RU (1) RU2222332C2 (et)
SA (1) SA99200234B1 (et)
SE (1) SE9802073D0 (et)
SK (1) SK286252B6 (et)
TR (1) TR200003666T2 (et)
TW (1) TWI252756B (et)
UA (1) UA87956C2 (et)
WO (1) WO1999064014A1 (et)
ZA (1) ZA200006943B (et)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
DE60103527T2 (de) 2001-07-02 2005-06-16 Chiesi Farmaceutici S.P.A. Optimierte Tobramycin-Formulierung zur Aerosolbildung
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
TW200300696A (en) 2001-11-01 2003-06-16 Inhale Therapeutic Syst Spray drying methods and related compositions
FI20020126A0 (fi) * 2002-01-23 2002-01-23 Orion Corp Koostumuksia pulmonaaliseen antoon
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
WO2008102128A2 (en) 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
AU2010253770B9 (en) 2009-05-29 2015-02-12 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
PT2538922T (pt) * 2010-02-25 2016-07-11 Andi-Ventis Ltd Formulação de composições para o tratamento de doenças inflamatórias
JP2013531056A (ja) * 2010-07-16 2013-08-01 シプラ・リミテッド Ｒ（＋）ブデソニド及び１以上の気管支拡張剤を含む医薬組成物
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2809666C (en) 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
CN102416179B (zh) * 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
AU2011314007B2 (en) 2010-09-29 2017-01-19 Pulmatrix, Inc. Cationic dry powders
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
JP2015509788A (ja) 2012-02-29 2015-04-02 パルマトリックス，インコーポレイテッド 吸入に適した乾燥粉末
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
TW201735914A (zh) * 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
IT202000006442A1 (it) 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203401A (en) 1979-01-29 1980-05-20 General Motors Corporation Evaporative emissions canister
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
ATE92762T1 (de) 1989-09-08 1993-08-15 Glaxo Group Ltd Medikamente.
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5119791A (en) 1991-06-07 1992-06-09 General Motors Corporation Vapor storage canister with liquid trap
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
EP1086697A2 (en) 1991-12-18 2001-03-28 AstraZeneca AB New combination of formoterol and budesonide
SG48301A1 (en) 1991-12-18 1998-04-17 Astra Ab New combination
US5408977A (en) 1993-08-23 1995-04-25 Walbro Corporation Fuel tank with carbon canister and shut-off valve
SK283569B6 (sk) 1993-10-01 2003-09-11 Astra Aktiebolag Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5511957A (en) 1994-09-27 1996-04-30 Walbro Corporation High capacity fuel pump and filter combination
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
DE69634416T2 (de) 1995-11-24 2005-12-29 Glaxosmithkline S.P.A. Chinolin-derivate
US5651349A (en) 1995-12-11 1997-07-29 Chrysler Corporation Purge system flow monitor and method
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SK184799A3 (en) 1997-06-27 2000-06-12 Astra Ab New combination of antiasthma medicaments
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US5957114A (en) 1998-07-17 1999-09-28 Ford Motor Company Evaporative emission canister for an automotive vehicle
US5924410A (en) 1998-07-20 1999-07-20 Ford Motor Company Evaporative emission canister for an automotive vehicle
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6227862B1 (en) * 1999-02-12 2001-05-08 Advanced Drivers Education Products And Training, Inc. Driver training system
EP1031725B1 (en) 1999-02-26 2004-12-29 Walbro Corporation Vehicle fuel system
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
US6237574B1 (en) 1999-04-20 2001-05-29 Ford Motor Company Evaporative emission canister for an automotive vehicle
US6136075A (en) 1999-05-03 2000-10-24 Westvaco Corporation Automotive evaporative emissions canister adsorptive restraint system
JP3646217B2 (ja) 1999-07-08 2005-05-11 愛三工業株式会社 キャニスタモジュール
US6374811B1 (en) 2000-10-04 2002-04-23 Ford Global Technologies, Inc. System and method for minimizing fuel evaporative emissions from an internal combustion engine

Also Published As

Publication number Publication date
SK18882000A3 (sk) 2001-07-10
CY1110376T1 (el) 2015-04-29
SK286252B6 (sk) 2008-06-06
NO20006253D0 (no) 2000-12-08
DK1085877T3 (da) 2008-06-09
EE05661B1 (et) 2013-06-17
EP1085877B1 (en) 2008-03-19
PT1085877E (pt) 2008-05-13
BR9911073A (pt) 2001-02-20
AR018410A1 (es) 2001-11-14
JP2002517450A (ja) 2002-06-18
SA99200234B1 (ar) 2007-03-10
CN100389771C (zh) 2008-05-28
HUP0103108A3 (en) 2002-11-28
CZ20004593A3 (cs) 2001-04-11
IS5752A (is) 2000-12-05
EP2266574A1 (en) 2010-12-29
SE9802073D0 (sv) 1998-06-11
AU771715B2 (en) 2004-04-01
US20040063676A1 (en) 2004-04-01
EP1316311A1 (en) 2003-06-04
DE69938390D1 (de) 2008-04-30
US9295644B2 (en) 2016-03-29
TWI252756B (en) 2006-04-11
IL139921A (en) 2006-10-05
PL344665A1 (en) 2001-11-19
MY129281A (en) 2007-03-30
AU4671099A (en) 1999-12-30
KR20010052721A (ko) 2001-06-25
NZ536279A (en) 2007-01-26
ATE389409T1 (de) 2008-04-15
TR200003666T2 (tr) 2001-06-21
NO20130269L (no) 2001-02-12
US20010049396A1 (en) 2001-12-06
EP1085877A1 (en) 2001-03-28
ES2302384T3 (es) 2008-07-01
CA2334411A1 (en) 1999-12-16
HK1035145A1 (en) 2001-11-16
ZA200006943B (en) 2002-02-27
ID27937A (id) 2001-05-03
DE69938390T2 (de) 2009-03-05
UA87956C2 (uk) 2009-09-10
RU2222332C2 (ru) 2004-01-27
WO1999064014A1 (en) 1999-12-16
IL139921A0 (en) 2002-02-10
CA2334411C (en) 2008-07-15
NO20140823L (no) 2001-02-12
NO20006253L (no) 2001-02-12
CN1305380A (zh) 2001-07-25
CZ300874B6 (cs) 2009-09-02
HUP0103108A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
EE05661B1 (et) Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma „gedate seisundite v„ltimiseks v?i raviks
EE04297B1 (et) Budesoniidi ja formoterooli uus kasutamine
BR9507656A (pt) Composto utilização de um composto composição farmacéutica e processos para o tratamento de um paciente que sofre de dor e para a preparação de um composto
BR9706822A (pt) Composição kit processo para tratamento de um distúrbio respiratório e utilização da composição do kit de formoterol de um sal ou solvato farmaceuticamente aceitável do mesmo e de budesonida
HUP0200852A3 (en) Combinations of formoterol and fluticasone propionate for asthma
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
FI970920L (fi) Trifenyylietyleenejä käytettäväksi osteoporoosin ehkäisyyn ja hoitoon
HUP0200014A3 (en) Pharmaceutical aerosol compositions containing fluoroalkanes, budesonide and formoterol
HUP0400529A3 (en) Use of chlorpromazine and pentamidine for preparation of pharmaceutical compositions for the treatment of neoplastic disorders
IL116505A0 (en) Compounds with progesterone-antagonistic and antiestrogenic action and the use thereof for the manufacture of pharmaceutical agents
DK0934057T3 (da) Medicinske aerosolformuleringer med formoterol
NO20021784L (no) Anvendelse av dipyridamol eller mopidamol for fremstilling av et medikament for behandling og forebygging av fibrin-avhengigmikrosirkulasjonsforstyrrelser
PL358375A1 (en) Medicaments for treating respiratory disorders comprising formoterol and fluticasone
AU3687400A (en) New combination of formoterol and mometasone in a pharmaceutical composition fortreating respiratory disorders, such as asthma, rhinitis and copd
PL365582A1 (en) Use of salmeterol and fluticasone propionate combination
FI950725L (fi) Trisyklisen yhdisteen käyttö muistin ja tajunnan häiriöiden hoitoon tarkoitettujen lääkevalmisteiden valmistukseen
EP1101493A3 (en) New combination of formoterol and budesonide
SI1085877T1 (sl) Uporaba sestavka, ki obsega formoterol in budezonid, za preprečevanje ali zdravljenje akutnega stanja
FI961494L (fi) Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi
SI1152753T1 (en) Combinations of formoterol and fluticasone propionate for asthma
WO2002019995A3 (en) Pharmaceutical combination containing salmeterol and fluticasone
IT1304852B1 (it) Miscela di piante medicinali per la prevenzione e la cura delleemorroidi.
BR9504442A (pt) Composto composiçao farmacêutica e método para o tratamento de uma condiçao médica
SI1156790T1 (en) Combinations of formoterol and mometasone furoate
BR1100852A (pt) Utilização dos compostos, e, composição farmacêutica